

DAKIN CAPITAL LLC



To All Federal and State Health Department Officials and Legislators:

A request is made to amend public health orders regarding COVID-19 to authorize any public venue to operate at 100% occupancy that:

- (1) implements air disinfection biotechnology and
- (2) demonstrates that the equipment substantially, continuously and quickly eliminates pathogens in the air.

In support of this request, the following information is provided:

1. Air disinfection biotechnology can eliminate pathogens in the air quickly and continuously.
2. Pathogen reduction can be precisely, scientifically measured and validated.
3. Air disinfection biotechnology has been utilized for decades in food processing, healthcare facilities and clean room manufacturing applications.
4. Implementation of air disinfection biotechnology in a room or building of a public venue can dramatically reduce the transmission of COVID-19.
5. Implementation of air disinfection biotechnology can make public venues far safer than full implementation of current public health orders mandating the use of masks, social distancing, and examination of people for COVID-19 symptoms.
6. Implementation of air disinfection biotechnology does not require distinguishing between 'essential' and 'non-essential' businesses or assigning elevated health threat levels to different types of businesses and public gatherings.
7. Implementation of air disinfection biotechnology would allow public venues to operate at 100% occupancy without the highly destructive impact of the current public health orders upon businesses and our economy.
8. Implementation of air disinfection biotechnology will protect the public against current and future disease-causing pathogens BEFORE they can rapidly spread. Future pandemics are an inevitable threat that will require immediate response to prevent loss of life while waiting for a vaccine.
9. The EPA is initiating a study of available air disinfection biotechnology equipment - <https://www.epa.gov/healthresearch/modeling-sars-cov-2-aerosols-and-evaluating-ways-inactivate-aerosolized-sars-cov-2>

Documentation regarding air disinfection biotechnology, laboratory tests regarding its efficacy and efficiency in eliminating airborne pathogens and a case study are available in support of this request.

Sincerely,

A handwritten signature in black ink, appearing to read 'Karl Dakin'.

Karl Dakin
Dakin Capital LLC
7148 S. Andes Circle
Centennial, CO 80016
720 296 0372
kdakin@dakincapital.com
<http://www.businessvaccine.us>